Hofseth Biocare ASA ((HOFBF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hofseth Biocare ASA has recently completed a clinical trial titled ‘A Randomized, Double-blind Clinical Trial Investigating the Efficacy of Salmon Bone Meal on Bone Mineral Density Among Perimenopausal Osteopenic Women.’ The study aimed to assess the effectiveness of salmon bone meal in preventing bone loss in women with reduced bone mass density, a condition known as osteopenia. This research is significant as it explores a potential dietary intervention to combat bone density loss in perimenopausal women, a demographic at increased risk for osteoporosis.
The intervention tested in the study was CalGo, a dietary supplement made from salmon bone meal enriched with Vitamin D3. Participants in the active group received four capsules daily, each containing approximately 500 mg of salmon bone meal, over a period of two years. The control group received a placebo of maltodextrin capsules.
The study was designed as a randomized, double-blind trial with a parallel intervention model. Both participants and researchers were blinded to the group assignments to ensure unbiased results. The primary purpose of the study was prevention, focusing on maintaining bone mineral density in the target population.
The study commenced on September 22, 2021, and was completed by September 22, 2025. These dates mark the start and end of the study, providing a timeline for the research and its findings. The last update was submitted on the same day as the study’s completion, indicating the finalization of data collection and analysis.
This study’s completion could have significant implications for Hofseth Biocare ASA’s market position. Positive results may enhance investor confidence and potentially boost the company’s stock performance. In the broader industry context, this development could influence competitors focusing on osteoporosis and bone health solutions.
The study is now completed, and further details can be accessed on the ClinicalTrials portal.